James Kevin Hanna, Senior Vice President, Controller & Chief Accounting Officer of Medical Properties Trust Inc . (NYSE:), recently sold 11,641 shares of the company’s common stock. The transaction, which took place on December 26, was executed at a price of $3.72 per share, amounting to $43,304. Following this sale, Hanna retained ownership of 366,913 shares of the company. According to a footnote in the filing, the sale is part of Hanna’s year-end tax planning, with the goal of potentially repurchasing the shares, depending on market conditions and compliance with related law and company policies. InvestingPro The analysis shows that the stock trades at a low Price/Book multiple of 0.42, with additional insights available in the comprehensive Pro Research Report covering MPW among 1,400+ US equities.

In other recent news, Medical Properties Trust reported several important developments. The company reported a GAAP net loss of $1.34 per share for the third quarter of 2024, while normalized funds from operations stood at $0.16 per share. In a strategic move, Medical Properties Trust has entered into a definitive agreement with Astrana Health for a deal valued at about $745 million, including the sale of most of its managed care platform Prospect.

The company expects to net about $200 million in cash proceeds after settling debts and other liabilities, with most of the cash proceeds expected in the first half of 2025. Hold the stock’s rating, and promoting significant maturities and high capital costs.

Medical Properties Trust also settled a defamation lawsuit against Viceroy Research, although details of the agreement remain undisclosed. These recent developments come amid the company’s poor capital allocation and risk management practices, as well as a substantial amount of maturing debt. Investors are expected to closely monitor the progress of Steward’s recently relocated hospitals and how effectively the company’s recapitalization is handled.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.